CRISPR-based gene-editing company GenKOre has partnered with diagnostic and life sciences company Revvity's Gene Delivery franchise to develop gene therapy treatments for ocular disorders such as Leber congenital amaurosis 10 (LCA10) and Usher syndrome type 2A (USH2A).
Under the collaboration, GenKOre will use its proprietary TaRGET (tiny nuclease, augment RNA-based genome-editing technology) gene-editing platform combined with Revvity's adeno-associated virus (AAV) vector development technology to develop in vivo gene-editing therapies. The collaboration also aims to validate TaRGET's applicability for in vivo therapy, expand its utility for rare diseases, and address unmet medical needs through genomic medicine.
GenKOre is a biotechnology company based in South Korea that specializes in gene-editing therapies. Its core technology, the TaRGET platform, includes various tools such as TaRGET-CUT, TaRGET-Adenine Base Editing (ABE), TaRGET-AI for gene activation and inhibition, and TaRGET-FREE for gene knock-in applications. This platform consists of hypercompact CRISPR-Cas tools, which can be delivered via a single AAV vector, unlike the CRISPR-Cas9 system.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.